Alx Oncology Holdings (ALXO)
$2.01
$-0.02
(-0.99%)
As on 04-Sep-2026 16:01EDT
Market cap
$278 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.3
-
Debt to Equity
0.1
-
Book Value
$--
-
EPS
$-1.1
-
Face value
--
-
Shares outstanding
138,276,997
6 Years Aggregate
CFO
$-353.42 Mln
EBITDA
$-456.09 Mln
Net Profit
$-446.46 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Alx Oncology Holdings (ALXO)
| 77.9 | 4.1 | 20.4 | 97.1 | -23.7 | -51.1 | -- |
|
BSE Sensex*
| -10.1 | -3.6 | 2.5 | -5.7 | 4.9 | 5.5 | 10.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Alx Oncology Holdings (ALXO)
| -32.3 | -88.6 | 32.1 | -47.6 | -75.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Alx Oncology Holdings (ALXO)
|
2.0 | 277.9 | 0.0 | -80.9 | -- | -99.8 | -- | 2.0 |
| 86.3 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 72.7 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 59.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 110.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 358.2 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 117.4 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 541.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 591.3 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 |
Shareholding Pattern
View DetailsAbout Alx Oncology Holdings (ALXO)
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a... combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California. Read more
-
Executive Chairman
Dr. Corey S. Goodman Ph.D.
-
Executive Chairman
Dr. Corey S. Goodman Ph.D.
-
Headquarters
South San Francisco, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Alx Oncology Holdings (ALXO)
What is the current share price of Alx Oncology Holdings (ALXO) Today?
The share price of Alx Oncology Holdings (ALXO) is $2.01 (NASDAQ) as of 04-Sep-2026 16:01 EDT. Alx Oncology Holdings (ALXO) has given a return of -23.67% in the last 3 years.
What is the current PB & PE ratio of Alx Oncology Holdings (ALXO)?
Since, TTM earnings of Alx Oncology Holdings (ALXO) is negative, P/E ratio is not available.
The P/B ratio of Alx Oncology Holdings (ALXO) is 2.01 times as on 04-Sep-2026, a 62 discount to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.60 |
2.36 |
2024 |
-0.65 |
0.78 |
2023 |
-4.54 |
3.85 |
2022 |
-3.72 |
1.74 |
2021 |
-10.43 |
2.40 |
What is the 52 Week High and Low of Alx Oncology Holdings (ALXO)?
The 52-week high and low of Alx Oncology Holdings (ALXO) are Rs 2.66 and Rs 1.01 as of 07-Sep-2026.
What is the market cap of Alx Oncology Holdings (ALXO)?
Alx Oncology Holdings (ALXO) has a market capitalisation of $ 278 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Alx Oncology Holdings (ALXO)?
Before investing in Alx Oncology Holdings (ALXO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.